Amino acid supplement first day
DrugAn orally administered supplement of the proprietary amino acid derivative
Other names: SeroVital™
NCT Number: NCT02987868
In a recent randomized, double-blind, cross-over clinical trial, serum growth hormone (hGH) increased 682% above baseline 120 minutes after oral administration of an amino acid-based dietary supplement (SeroVital), p=0.01 vs placebo. In contrast to the mechanism of hGH stimulation by ghrelin, the investigators hypothesize that the supplement suppresses somatostatin, a know inhibitor of both hGH and TSH. To test this hypothesis, the investigators measured triiodothyronine (T3) after administration of the amino acid-base supplement.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Two molecular targets that regulate the synthesis and secretion of human growth hormone (hGH) include 1) ghrelin, an endogenous ligand secreted by the stomach that also has appetite-stimulation properties distinct from its hGH-stimulating effects, and 2) somatostatin, a family of 14 and 28 amino acid peptides that act as a potent noncompetitive inhibitor of the release of hGH. the investigators recently reported that oral administration of a 2.9g/dose of SeroVital, a blend of l-lysine HCl, l-arginine HCL, oxo-proline, N-acetyl-l-cysteine, l-glutamine, and schizonepeta (aerial parts) powder, leads to a significant 682% mean increase in endogenous hGH levels in male and female subjects in a period of 120 minutes following acute consumption. In the work presented here, the investigators seek to characterize the mechanistic target associated with this measured increase in endogenous hGH by SeroVital, which the investigators hypothesize to be somatostatin. The investigators test this hypothesis by assaying thyroid function, a secondary inhibition target of somatostatin. The investigators further compare our findings to ghrelin-based hGH secretagogues.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An orally administered supplement of the proprietary amino acid derivative
Other names: SeroVital™
A non-active orally administered supplement of the proprietary amino acid derivative
Other names: Non-active
An orally administered supplement of the proprietary amino acid derivative
Other names: SeroVital™
A non-active orally administered supplement of the proprietary amino acid derivative
Other names: Non-active
Time frame: 0-120 minutes, at Baseline and post dose, week 1 and week 3
Measure Triiodthyronine at times 0-120 minutes on two occasions about one week apart. On one occasion, the proprietary amino acid derivative blend will be given orally at time 0 in capsule form, and on the other occasion the capsules will contain no amino acids.
Pennington Biomedical Research Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05253287
Atrophy, Digestive System Disease
Chandigarh, Uttarakhand, India
View Trial DetailsNCT03091374
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Montreal, Quebec, Canada
View Trial DetailsNCT05195437
Growth Hormone Treatment
Paris, France
View Trial DetailsNCT04938466
Bone Diseases, Bone Diseases, Developmental
Minneapolis, Minnesota, United States
View Trial Details